BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 28659311)

  • 1. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
    Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
    Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
    [No Abstract]   [Full Text] [Related]  

  • 2. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
    Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
    Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
    Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
    Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
    Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
    Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
    Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
    J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
    Leivas A; Valeri A; Córdoba L; García-Ortiz A; Ortiz A; Sánchez-Vega L; Graña-Castro O; Fernández L; Carreño-Tarragona G; Pérez M; Megías D; Paciello ML; Sánchez-Pina J; Pérez-Martínez A; Lee DA; Powell DJ; Río P; Martínez-López J
    Blood Cancer J; 2021 Aug; 11(8):146. PubMed ID: 34392311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
    Han Y; Xie W; Song DG; Powell DJ
    J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
    Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
    Front Immunol; 2019; 10():2361. PubMed ID: 31649672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells engineered with full-length NKG2D linked to signaling domains of 4-1BB and CD3ζ show enhanced antitumor activity.
    Teng X; Rong Z; Li S; Yang W; Lu Z
    Immunol Cell Biol; 2023 May; 101(5):458-464. PubMed ID: 36811384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
    Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
    Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
    Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia
    Ibáñez-Navarro M; Fernández A; Escudero A; Esteso G; Campos-Silva C; Navarro-Aguadero MÁ; Leivas A; Caracuel BR; Rodríguez-Antolín C; Ortiz A; Navarro-Zapata A; Mestre-Durán C; Izquierdo M; Balaguer-Pérez M; Ferreras C; Martínez-López J; Valés-Gómez M; Pérez-Martínez A; Fernández L
    Front Immunol; 2023; 14():1187665. PubMed ID: 37928520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKG2D CARs as cell therapy for cancer.
    Sentman CL; Meehan KR
    Cancer J; 2014; 20(2):156-9. PubMed ID: 24667963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
    Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
    Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
    Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
    Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
    Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.